|
Market Closed -
NYSE
01:00:02 10/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 85.25 USD | +1.67% |
|
-5.54% | +7.42% |
| 11-07 | CVS Health Insider Bought Shares Worth $2,001,315, According to a Recent SEC Filing | MT |
| 11-06 | Goldman Sachs Adjusts Price Target on CVS Health to $115 From $120 | MT |
| Market Cap | 107B 95.76B 88.12B 79.97B 152B 10,056B 155B 1,054B 420B 5,384B 403B 394B 16,956B | P/E 2026 * |
12.1x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 161B 144B 132B 120B 228B 15,117B 233B 1,585B 632B 8,093B 605B 592B 25,490B | EV / Sales 2026 * |
0.38x | EV / Sales 2027 * | 0.36x |
| Free-Float |
71.22% | Yield 2026 * |
3.13% | Yield 2027 * | 3.2% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CVS | Delayed | |
CBOE
| CVS | Real-time | |
|
Tradegate
| CVS | Real-time | |
|
Börse Stuttgart
| CVS | Delayed | |
|
Xetra
| CVS | Delayed | |
|
Boerse Muenchen
| CVS | Real-time | |
|
Mexican S.E.
| CVS * | End-of-day quote | |
|
Deutsche Boerse AG
| CVS | Delayed | |
|
London S.E.
| 0HRS | Delayed | |
|
Wiener Boerse
| CVS | End-of-day quote | |
|
Santiago S.E.
| CVS | End-of-day quote | |
|
Lima
| CVSUS | End-of-day quote | |
|
Borsa Italiana
| 1CVS | End-of-day quote | |
|
Santiago S.E.
| CVSCL | End-of-day quote | |
|
CBOE
| 0HRS | Real-time | |
|
CBOE
| Real-time | ||
|
Swiss Exchange
| CVS | Delayed | |
|
Swiss Exchange
| CVS | Delayed |
Last Transcript: CVS Health Corporation
| 1 day | +1.67% | ||
| 1 week | -5.54% | ||
| Current month | -5.54% | ||
| 1 month | -2.90% | ||
| 3 months | -10.92% | ||
| 6 months | -5.85% | ||
| Current year | +7.42% |
| 1 week | 77.33 |  | 91.89 |
| 1 month | 77.33 | | 95.26 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 17/10/2024 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 12/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 01/03/2007 |
Anne Finucane
BRD | Director/Board Member | 73 | 20/01/2011 |
| Director/Board Member | 71 | 05/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/05/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 31/05/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% | ||
| 21/05/26 | Glenview Capital Management LLC
| Sell | Company | -748,462 | 0.0584% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.67% | -5.54% | +7.93% | +24.00% | 107B | |
| +2.00% | +6.70% | +5.93% | +118.05% | 103B | |
| +3.13% | -22.67% | +60.54% | +675.01% | 45.05B | |
| +1.18% | +9.80% | +10.16% | +103.96% | 32.96B | |
| +1.43% | +2.89% | +47.13% | +80.64% | 29.77B | |
| +1.58% | +3.12% | +44.66% | +94.55% | 28.12B | |
| +2.00% | +5.76% | +40.80% | +429.11% | 22.55B | |
| -0.37% | +0.09% | -19.78% | -19.41% | 20.05B | |
| -0.26% | -1.91% | -7.00% | +28.33% | 16.76B | |
| +2.98% | +3.38% | +108.66% | - | 13.96B | |
| Average | +1.53% | -1.57% | +29.90% | +170.47% | 42B | |
| Weighted average by Cap. | +1.73% | -2.46% | +21.69% | +156.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 421B 376B 346B 314B 595B 39,468B 610B 4,137B 1,649B 21,130B 1,580B 1,547B 66,551B | 430B 384B 354B 321B 608B 40,348B 623B 4,229B 1,686B 21,601B 1,616B 1,581B 68,034B |
| Net income | 9.03B 8.06B 7.42B 6.73B 12.76B 846B 13.07B 88.71B 35.36B 453B 33.89B 33.16B 1,427B | 9.34B 8.34B 7.67B 6.96B 13.19B 875B 13.52B 91.76B 36.58B 469B 35.05B 34.3B 1,476B |
| Net Debt | 53.99B 48.19B 44.35B 40.25B 76.27B 5,061B 78.17B 530B 211B 2,709B 203B 198B 8,533B | 49.56B 44.24B 40.71B 36.94B 70.01B 4,645B 71.75B 487B 194B 2,487B 186B 182B 7,833B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/11/26 | $85.25 | +1.67% | 11,186,731 |
| 06/11/26 | $83.85 | +3.10% | 16,099,672 |
| 05/11/26 | $81.33 | +1.71% | 19,930,575 |
| 04/11/26 | $79.96 | -12.53% | 34,289,772 |
| 03/11/26 | $91.41 | +3.28% | 19,630,048 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
